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Abstract: Vasopressors and inotropes are routinely used in acute myocardial infarction (AMI)
related cardiogenic shock (CS) to improve hemodynamics. We aimed to investigate the effect of
routinely used vasopressor and inotropes on mortality in AMI related CS. A systematic search of
MEDLINE, EMBASE and CENTRAL was performed up to 20 February 2019. Randomized and
observational studies reporting mortality of AMI related CS patients were included. At least one
group should have received the vasopressor/inotrope compared with a control group not exposed to
the vasopressor/inotrope. Exclusion criteria were case reports, correspondence and studies including
only post-cardiac surgery patients. In total, 19 studies (6 RCTs) were included, comprising 2478 CS
patients. The overall quality of evidence was graded low. Treatment with adrenaline, noradrenaline,
vasopressin, milrinone, levosimendan, dobutamine or dopamine was not associated with a difference
in mortality between therapy and control group. We found a trend toward better outcome with
levosimendan, compared with control (RR 0.69, 95% CI 0.47–1.00). In conclusion, we found insufficient
evidence that routinely used vasopressors and inotropes are associated with reduced mortality in
patients with AMI related CS. Considering the limited evidence, this study emphasizes the need for
randomized trials with appropriate endpoints and methodology.
Keywords: cardiogenic shock; inotrope; vasopressor; myocardial infarction; low cardiac output;
shock; review
1. Introduction
Cardiogenic shock (CS) is a low cardiac output state that leads to hypoperfusion and subsequent
multi-organ failure with high mortality rates [1,2]. The commonly used clinical definition of CS is
based on hemodynamic criteria and signs of hypoperfusion [3].
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Vasopressors and inotropes are routinely used in the treatment of CS to improve hemodynamics and
restore organ perfusion. Scientific statements recommend noradrenaline as the first-line pharmacologic
treatment strategy in CS, with the addition of inotropes in patients with persistent low cardiac
output [4,5].
Acute myocardial infarction (AMI) is a common cause of CS, accounting for at least 30% of the
cases [6–8]. Vasopressors and inotropes are used in patients with AMI related CS, in the assumption
that they improve and maintain adequate coronary perfusion and cardiac output. However, these drugs
are also associated with arrhythmias and may increase the myocardial oxygen demand by increasing
the contractility, afterload and/or by reducing coronary perfusion [9].
Therefore, we performed a systematic review to examine the current evidence on the effect of
different vasopressors and inotropes on mortality in patients with AMI related CS.
In this systematic review and meta-analysis, we addressed the following questions: (1) Is treatment
with adrenaline, noradrenaline, vasopressin, milrinone, levosimendan, dobutamine or dopamine
associated with reduced mortality in patients with AMI related CS? and (2) What is the effect of these
drugs on complications and safety outcomes (e.g., duration of supportive measures, length of intensive
care unit (ICU) stay, hemodynamic effects, organ failure and therapy-related complications)?
2. Experimental Section
This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis
PRISMA guidelines. [10] The protocol was registered in the PROSPERO database (CRD42018107644).
2.1. Selection Criteria
To qualify for inclusion, studies must have reported on mortality in CS patients and include
patients with AMI. Furthermore, studies were considered for inclusion if outcome data were reported
in (A) patients treated with an inotrope or vasopressor and (B) a control group that was not exposed to
the (same) inotrope or vasopressor therapy. The following inotropes and vasopressors were included:
(1) adrenaline, (2) noradrenaline, (3) vasopressin, (4) milrinone, (5) levosimendan, (6) dobutamine
and (7) dopamine. Studies comparing different dosages of inotropes or vasopressors were excluded,
unless an unexposed control arm (B) was present. We excluded studies that reported only on
post-cardiac surgery patients. We expected very few evidences from randomized controlled trials
(RCTs) and therefore we included all study designs except case reports and correspondences.
2.2. Search Strategy
A medical information specialist (JL) conducted a systematic search of the following databases:
MEDLINE (OVID), EMBASE (OVID), and the Cochrane Central Register of Controlled Trials
(CENTRAL) from inception to 20 February 2019. The search included both controlled terms
(i.e., MeSH-terms) and free-text words for: (1) cardiogenic shock (or shock /low cardiac output
and MI) and (2) inotrope/vasopressor drugs (see Appendix A). Non-human studies, narrative reviews
and editorials were excluded. No further restrictions were applied. Reference lists and citing articles of
identified relevant papers were crosschecked. The search was adapted in the case of additional relevant
studies. The bibliographic records retrieved were imported using EndNote X8 and duplications
were removed.
2.3. Data Extraction and Quality Assessment
Two researchers (either MK, WL, DO or VH) independently screened titles and abstracts of the
retrieved papers and excluded studies based on the selection criteria. Subsequently, two researchers
independently assessed the eligibility of the potentially eligible papers in full text. Conference papers
were considered for inclusion if they met selection criteria and necessary data were available. After the
eligible studies were identified, two researchers (MK and VH) independently performed data extraction.
We attempted to retrieve unclear or missing data by contacting the corresponding authors of studies.
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The quality of the individual studies was assessed using the Revised Cochrane risk-of-bias (RoB 2.0)
for RCTs and the Newcastle–Ottawa scale (assessed on mortality outcome level) for non-randomized
studies [11,12]. The overall quality of evidence was assessed using the GRADE’s approach [13].
Any discrepancies between the researchers were solved by discussion and/or the involvement of a
third researcher (JH).
2.4. Data Analysis
The primary outcome was mortality, defined as short-term (<90 day) and long-term (≥90 day)
mortality. The therapy group was defined as the examined vasopressor/inotrope. The control group
was constructed from the cumulated comparator of the different studies. We summarized mortality
in a quantitative manner, using a random-effects model, presented with relative risks (RR) and 95%
confidence intervals (CI). Heterogeneity was evaluated using Chi-squared and I-squared test, with the
significance set at a p-value of 0.10. An I-squared test of >40% was considered indication of substantial
heterogeneity. Sensitivity analyses (excluding conference papers and/or observational studies) were
applied where appropriate. Review Manager (version 5.3) was used for statistical analysis. We
also provided a narrative synthesis of the included studies regarding study population, therapies
and outcome(s) and described the following secondary outcomes: duration of supportive measures,
length of ICU stay, hemodynamic effects, organ failure and therapy-related complications.
3. Results
3.1. Search Results
Of the 6187 unique publications retrieved, 110 were assessed full text for eligibility and 19 studies
were included in the review. The reasons for exclusion are listed in Figure 1.
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3.2. Study Characteristics
Study characteristics of the 19 included studies are presented in Table 1.
Table 1. Summary of included studies (n = 19) on inotrope/vasopressor therapy in cardiogenic shock.
Study Year Country Center Setting Inclusion Period Follow-up Overall N CS N
Cronin 1965 Canada Single Retrospective cohort 1952–1961 10 years 140 140
Moulopoulos 1993 Greece Single Retrospective cohort 1978–1991 1 month 55 55
Andriange 1971 Belgium Single Retrospective cohort 1967–1970 1 year 450 45
Samimi-Fard 2007 Spain Single Randomized trial 2003–2004 1 year 22 22
El Mokhtari 2007 Germany Single Retrospective cohort - 1 year 20 20
Fuhrmann 2008 Germany Single Randomized trial 2003–2005 30 days 32 32
Myburgh 2008 Australia Multi Randomized trial 2004–2006 90 days 280 128
Christoph 2008 Germany Single Prospective cohort 2003–2005 - 22 22
De Backer 2010 Belgium Multi Randomized trial 2003–2007 1 year 1679 280
Omerovic 2010 Sweden Single Prospective cohort 2004–2006 1 year 94 94
Caetano 2012 Portugal - Retrospective cohort(conference paper) -
10.6 ± 10.9
months 37 37
Huseby 2013 Norway Single Randomized trial 2006–2010 6 months 61 9
Affronti 2013 Italy Single Retrospectivecase-control 2011 - 17 17
Katsytadze 2013 Ukraine - Retrospective cohort(conference paper) - 1 year 27 27
Yagi 2015 Japan Multi Prospective cohort(conference paper) 2012–2014 30 days 979 240
Tarvasmaki 2016 Finland Multi Prospective cohort 2010–2012 90 days 216 216
Levy 2018 France Multi Randomized trial 2011–2016 60 days 57 57
Vally 2019 France Single Retrospective cohort 2010–2017 30 days 150 150
Lewis 2018 USA Single Retrospective cohort 2013–2015 In-hospital 100 100
CS: cardiogenic shock.
3.3. Participants
The overall patient population included in the studies and baseline characteristics of the CS
patients are described in the Supplementary Materials, Table S1. In total, 4441 patients were included,
of whom 2478 CS patients. All included studies included at least a subgroup with AMI related CS,
and 10 studies included only patients with AMI related CS. Overall, there were 137 CS patients treated
with adrenaline, 594 CS patients treated with noradrenaline, 8 CS patients treated with vasopressin,
50 CS patients treated with milrinone, 209 CS patients treated with levosimendan, 200 CS patients
treated with dobutamine and 367 CS patients treated with dopamine.
3.4. Intervention
Criteria for initiation of vasopressor or inotrope therapy differed amongst the various studies and
are described in the Supplementary Materials (Table S1).
3.5. Comparison
We identified six RCTs with different comparisons [14–19]; noradrenaline versus adrenaline in
patients with AMI related CS (Levy, 2018), noradrenaline versus adrenaline in patients that required a
vasopressor for any cause (Myburgh, 2008), noradrenaline versus dopamine in patients with shock
of all-causes (De Backer, 2010 = SOAP II trial), dobutamine versus levosimendan in STEMI patients
with CS after PCI (Samimi-Fard, 2007), levosimendan versus placebo in acute STEMI patients with
clinical signs of heart failure <48 h after primary PCI (Huseby, 2013 = LEAF trial) and levosimendan
versus enoximone in patients with refractory CS < 2 h after PCI (Fuhrmann, 2008). Of note, in all of the
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included studies, the control group was exposed to some type of vasopressor or inotrope other than
the drug that was examined (noradrenaline in most cases).
3.6. Quality of Studies
The overall body of evidence regarding the primary outcome was graded low, assessed using
the GRADE’s approach. This grade was based on only limited evidence from randomized trials
with serious inconsistency and risk of bias. The individual quality assessment of the studies is
presented in the Supplementary Materials; Table S2 for the randomized studies and Table S3 for the
observational studies.
3.7. Mortality Outcomes
The synthesis of mortality is shown in Figure 2 for short-term mortality and Figure 3 for
long-term mortality. Mortality outcomes of CS patients in the individual studies are described in the
Supplementary Materials, Table S4.
3.7.1. Adrenaline vs. Constructed Control
Three of the included studies reported on patients treated with adrenaline [14,15,20]. Levy et al.
and Myburgh et al. performed an RCT comparing the effect of adrenaline and noradrenaline on
hemodynamic parameters (respectively, cardiac index evolution and achievement of MAP goal > 24 h).
Tarvasmaki et al. performed an observational study in which they compared 90-day mortality of
patients with acute CS treated with adrenaline (also for noradrenaline, vasopressin, levosimendan,
dobutamine, dopamine) versus a non-exposed control group. The two RCTs comparing adrenaline
with noradrenaline evaluated 28-day mortality. Their pooled estimate showed no treatment effect of
adrenaline on short-term mortality (RR 1.22, 95% CI 0.60–2.50, heterogeneity I2 = 58%). Pooled estimate
of the studies that reported on long-term mortality also showed no treatment effect of adrenaline
(RR 1.37 95% CI 0.45–4.16; n = 2 studies), with substantial heterogeneity between the studies (I2 =
94%).
3.7.2. Noradrenaline vs. Constructed Control
Six studies (three RCTs) reported on patients treated with noradrenaline [14–16,20–22].
Treatment with noradrenaline was not associated with a difference in short-term mortality
(RR 0.84, 95% CI 0.63–1.10; n = 4 studies, heterogeneity I2 = 30%). Sensitivity analysis including only
the three RCTs that reported on short-term mortality also showed no treatment effect of noradrenaline
(RR 0.77, 95% CI 0.56–1.06; I2 = 26%). Likewise, the pooled estimate showed no treatment effect
of noradrenaline on long-term mortality (RR 1.31, 95% CI 0.80-2.15; n= 3 studies), with substantial
heterogeneity between the studies (I2 = 81%).
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Figure 3. Forest plot demonstrating long-term (≥90 day) mortality of cardiogenic shock patients treated
with a vasopressor/inotrope versus a constructed control group.
3.7.3. Vasopressin vs. Constructed Control
Mortality outcomes of vasopressin treatment were available in one observational study [20].
In this study 90 day mortality consisted of 7 deaths out of 8 patients (87.5%) treated with vasopressin,
compared with 81 deaths out of 208 patients (38.9%) in the control group (RR 2.25, 95% CI 1.64–3.07).
3.7.4. Milrinone vs. Constructed Control
Mortality outcomes of milrinone treatment were available in one observational study [23].
Lewis showed no treatment effect of milrinone on in-hospital mortality, compared with dobutamine.
There was 1 death out of 50 patients (2.0%) treated with milrinone, compared with 5 deaths out of
50 patients (10.0%) in the control group (RR 0.20, 95% CI 0.02–1.65).
3.7.5. Levosimendan vs. Constructed Control
Ten studies (three RCTs) reported mortality outcomes of patients treated with
levosimendan [17–20,24–29]. In six studies that reported on short-term mortality, the overall trend of the
pooled estimate favored levosimendan therapy over the constructed control (RR 0.69, 95% CI 0.47–1.00;
participants = 352, heterogeneity I2 = 39%). In sensitivity analysis excluding the conference paper,
levosimendan was associated with favorable outcome, compared to the constructed control (RR 0.61,
95% CI 0.41–0.90, n = 5 studies). Pooled estimate showed no treatment effect of levosimendan on
long-term mortality (RR 0.90, 95% CI 0.65–1.23; studies, n = 5, with low heterogeneity I2 = 4%).
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Sensitivity analysis including only the two RCTs that reported long-term mortality showed similar
results (RR 0.78, 95% CI 0.36–1.70; n = 3 studies). We also performed additional sensitivity analysis for
long-term mortality excluding only the conference paper (RR 0.95, 95% CI 0.65–1.40, n = 4 studies).
3.7.6. Dobutamine vs. Constructed Control
Five studies (one RCT) reported on patients treated with dobutamine [17,20,23,30,31]. Pooled
estimate showed no treatment effect of dobutamine on short-term mortality (RR 1.84, 95% CI 0.43–7.92,
substantial heterogeneity I2 = 56%). Likewise, the pooled estimate of studies that reported on
long-term mortality showed no treatment effect of dobutamine (RR1.13, 95% CI 0.66–1.93; n = 3 studies,
low heterogeneity I2 = 19%).
3.7.7. Dopamine vs. Constructed Control
Four studies (one RCT) reported on patients treated with dopamine [16,20,22,32]. Three studies
(one RCT) reported short-term mortality. The pooled estimate showed no treatment effect of dopamine
(RR 1.01 95% CI 0.65–1.57, substantial heterogeneity I2 = 84%). Sensitivity analysis without the
conference paper showed similar results (RR 1.04, 95% CI 0.51–2.12; n = 2 studies). There was also
no treatment effect of dopamine on long-term mortality (RR 0.94, 95% CI 0.81–1.10; n= 2 studies,
low heterogeneity I2 = 0%).
3.8. Secondary Outcomes
We summarized the primary endpoint, results and secondary outcomes from the included studies
in Table S5, Supplementary Materials. Data on adverse events and safety outcomes were not always
available in the studies, but arrhythmic events were reported frequently.
4. Discussion
In the present article, we reviewed the current evidence on outcomes of vasopressors and inotropes
in patients with AMI related CS and found that adrenaline, noradrenaline, milrinone, levosimendan,
dobutamine and dopamine were not associated with a difference in short-term or long-term mortality.
The quality of the evidence was low as studies were mostly observational, heterogeneous and included
a small number of patients.
We found a positive trend in the pooled estimate of six studies reporting on short-term mortality
toward treatment with levosimendan (RR 0.69, 95% CI 0.47–1.00, low-level of evidence). Vasopressin was
associated with a difference in long-term mortality in favor of the control group. However, this was
based on the results of one observational trial including 8 CS patients treated with vasopressin,
compared with a much larger control group. These results are highly biased since the study had a
small sample size, was non-randomized and did not adjust for baseline differences.
Our results extend a 2018 Cochrane review with a smaller size (including 13 RCTs;
2001 participants) [33]. The scope of this review was significantly different from ours, since the
majority of the included patients had acute on chronic heart failure or cardiac surgery complicated by
low cardiac output syndrome (LCOS) or CS, instead of AMI related CS. In this review the effect of
inotropes and vasodilators on mortality in patients with LCOS or CS was evaluated, demonstrating
low-quality evidence that suggested a short-term mortality benefit of levosimendan compared with
dobutamine. None of the other examined inotropes or vasodilators were associated with differences
in mortality.
Furthermore, a previous Cochrane review published in 2016, investigated vasopressor therapy for
hypotensive shock of all etiologies (mostly septic patients) [34]. Again, in this review patients with
AMI related CS were underrepresented and there was no subgroup analysis performed according
to shock type. Although none of the vasopressors in this review was associated with a difference in
mortality, dopamine significantly increased the risk for arrhythmias compared to noradrenaline.
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The ESC 2017 Guidelines for the management of AMI in patients presenting with ST-segment
elevation recommend dobutamine as the initial therapy in predominant low cardiac output (Class IIb) [5].
Noradrenaline is recommended in CS and severe hypotension (Class IIb) based on one study
(De Backer et al.) reporting a lower rate of arrhythmias and a trend toward lower mortality compared
with dopamine in a subgroup analysis [16]. However, there are some methodological concerns
regarding this trial since randomization was not stratified and the test for subgroup differences
(p = 0.87) suggested that the effect was not significant. Also, the subgroup of CS patients was
heterogeneous, consisting of AMI, chronic heart failure and post-cardiotomy patients. A recently
published RCT examined reduced exposure to noradrenaline through permissive hypotension (lower
MAP target) in patients with vasodilatory hypotension aged 65 year or older and found that reduced
noradrenaline was not harmful and might even be beneficial [35].
Despite the lack in evidence showing efficacy of treatment with vasopressors and inotropes in AMI
related CS, there is a widespread use in clinical practice. Physicians are unlikely to refrain from the use
of any vasopressor or inotrope in patients with CS. Of note, none of the included studies in this review
had a control group that did not receive any vasopressor or inotrope. Therefore, the current literature
doesn’t tell us much about the effectiveness of any agent vs. placebo but only against each other. In other
words, these drugs are either equally effective or equally ineffective. Furthermore, it is important to
realize that hemodynamic parameters do not necessarily correlate with tissue perfusion and patient
outcomes. It has not been proven that hemodynamic improvement in CS patients results in better
outcome. Currently, CS is a clinical diagnosis that has not been well defined, and there is significant
heterogeneity in CS definition among the studies used for meta-analysis. Therefore, the current
level of evidence is insufficient to draw conclusions on whether vasopressors/inotropes are effective.
However, we do believe it is of clinical importance to review and summarize the current evidence
regarding routinely used therapies. This systematic review and meta-analysis is the first to report
outcomes of commonly used vasopressor/inotropic therapies in patients with CS complicating AMI.
The authors believe that rigorous studies exploring the efficacy of vasopressors and inotropes
with appropriate endpoint and methodology are advocated. Not only to compare the efficacy between
different drugs and dosages but also to ascertain whether these drugs are effective in reducing mortality.
Several RCTs that challenged the current pharmacological treatment in patients with out-of-hospital
cardiac arrest (OHCA) demonstrated that although the administration of adrenaline was associated
with improved short-term survival in OHCA, it did not affect survival with favorable neurological
outcome [36–38]. It is important to also initiate large placebo-controlled, double-blind, RCTs in CS
patients to definitively establish the effect of pharmacological therapy. Studying the CS population
in an RCT is challenging but feasible with the adoption of adequate methodology and statistical
plan analysis.
In the present study, several decisions were made by the research team that could possibly limit
our conclusion. The aim of this study was to summarize the evidence regarding vasopressor and
inotropic treatment of a selected patient group (AMI related CS), since patients presenting with a
non-hypotensive low-output status differ significantly in their treatment goal and strategy. Due to the
limited number of studies exclusively reporting on patients with AMI related CS, we also included
studies with mixed etiologies, as long as there were AMI patients included in the cohort.
Another limitation of our review was that the included studies were very heterogeneous in
terms of participants, interventions, comparisons and outcomes. Specific subgroup analysis to
reduce heterogeneity was not possible, due to the limited number of studies that were available
regarding the different drugs. Moreover, single center, retrospective studies with a small sample
size were included, which are likely to have significant selection bias. Furthermore, we included
all study designs, without any publication or language restriction. It may be debatable to include
conference papers (of which the methodological quality could not be properly assessed due to limited
information). However, including conference papers may also reduce the effect of potential publication
bias. Moreover, randomized evidence is very limited, and observational data is informative in
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assessing therapy-related complications and safety outcomes. To examine the best possible level of
evidence, we performed sensitivity analyses where possible excluding the conference papers and/or
observational studies.
5. Conclusions
There is insufficient evidence that routinely used vasopressors and inotropes are associated with
reduced mortality in patients with AMI related CS. Considering the limited evidence, this study
emphasizes the need for proper randomized trials.
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Appendix A Search strategies
Medline
Database(s): Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed
Citations and Daily 1946 to February 19, 2019
Search Strategy: 2019-02-20
# Searches Results
1 shock, cardiogenic/ 7757
2 (cardiogen* adj9 shock*).tw,ot,kw,kf. 10393
3 (circulator* adj3 shock*).tw,ot,kf. 1251
4 coron* shock*.tw,ot,kw,kf. 20
5 acute circulatory fail*.tw,ot,kw. 247
6
*shock/dt not (septic or sepsis or bacter*em* or infect* or endotoxin* or heat shock or HSP* or
anaphyl* or allergic or vasodilat* or osmotic or h?emorr* or bleeding or toxic or neurogen* or
burn* or shock-wave or shock-resistant or hypovolemic or electroconvuls* or distributive
shock*).ti.
711
7
((undifferent* or undiagnos* or different or various or variety or type or types or kind or kinds
or forms or states or etiologies) adj2 (shock* not heat shock*)).tw.
1662
8 or/1-7 [I = cardiogenic shock ] 16778
9
myocardial ischemia/ or acute coronary syndrome/ or exp myocardial infarction/ or
percutaneous coronary intervention/ or angioplasty, balloon, coronary/ or myocardial
revascularization/ or coronary artery bypass/
275348
10
(((myocard* or heart or card* or ST) adj3 (infarct* or isch?em*)) or (coronary intervent* or STEMI
or PCI or angioplast* or post-isch* or postisch* or postinfarct* or post-infarct* or MI or AMI or
myocard* revasc* or coronary artery bypass* or CABG or aortocoronary bypass* or coronary
bypass*)).tw,ot,kf.
379295
11 9 or 10 [MI] 454472
12
(shock/ or shock.ti,kw.) not (electric countershock/ or (septic or sepsis or bacter*em* or infect* or
endotoxin* or heat shock or HSP* or anaphyl* or allergic or vasodilat* or osmotic or h?emorr* or
bleeding or toxic or neurogen* or burn* or shock-wave or shock-resistant or hypovolemic or
electroconvuls* or distributive shock*).ti.) [shock general]
30283
13 cardiac output, low/ 5447
14
((low* or diminish* or decreas* or declin* or reduc* or negligibl* or fall*) adj2 (card* or heart) adj
output*).tw,kf.
8066
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15 ((low* or diminish* or decreas* or declin* or reduc* or negligibl*) adj output*).tw,kf. 1988
16 cardiac output low.tw,kf,ot. 51
17 (LCOS or COS or LCO).tw,ot,kw. 17758
18 ((instab* or unstab*) adj1 h?emodyn*).tw,kf. 7625
19 or/12-18 [shock, low CO] 69271
20 11 and 19 [ II = MI + CO ] 8371
21 8 or 20 [ I II ] 20946
22
(animals/ not humans/) or (porcine or piglet or pig or pigs or rat or rats or dogs or dog or
canine).ti. or ph?eochrom*.mp.
4677715
23
(review or editorial).pt. not ((case reports or clinical trial or clinical trial phase iii or clinical trial
phase iv or comparative study or controlled clinical trial or evaluation studies or letter or meta
analysis or randomized controlled trial).pt. or case-control studies/ or exp cohort studies/ or
cross-sectional studies/ or (systematic adj3 (literature or review)).tw,ot,kf.)
2590121
24 22 or 23 7115287
25 21 not 24 [ I II - human not review,editorial] 16394
26 cardiotonic agents/tu, ad 8559
27 catecholamines/ad, tu 948
28 (cardiotonic* or inopressor* or inodilator*).tw,ot,kw. 2445
29
(catecholamines or inotropes or vasopressors or ((catecholamine or inotrop* or vasopressor) adj3
(support or solution* or infusion* or dosing or dose* or dosage* or prescri* or "use" or therap* or
treat* or cotreat* or administ* or requir* or need* or superior or first-line or "add" or added or
addition or adding or receiv* or receipt or regimen* or alone or combin* or plus or compar* or
vs or versus or assigned or allocat* or randomi?ed or effectiveness or efficacy or drug* or agent*
or substance* or group))).tw,ot,kf.
48357
30 dopamine/ 67481
31 (dopamin* or hydroxytyramin* or Intropin*).tw,ot,kw. 145939
32 dobutamine/ 6002
33 dobutamin*.tw,ot,kw. 8454
34 noradrenaline/ 84076
35 (norepinephrin* or noradrenalin*).tw,ot,kw. 92575
36 adrenaline/ 54084
37 (epinephrin* or adrenalin*).tw,ot,kw. 56754
38 milrinone/ 1316
39 milrinon*.tw,ot,kw. 1847
40 vasopressins/ 21322
41 vasopressin*.tw,ot,kw. 33741
42 simendan/ 1042
43 (simendan or levosimend*).tw,ot,kw. 1286
44 or/26-43 [ inotropes/vasopressors ] 378001
45 25 and 44 [ cardiogenic shock + inotropes/vasopressors ] 2050
46 remove duplicates from 45 [ cardiogenic shock + inotropes/vasopressors -deduplicated ] 2047
Embase
Database(s): Embase Classic+Embase 1947 to 2019 February 19
Search Strategy: 2019-02-20
# Searches Results
1 cardiogenic shock/ 24059
2 (cardiogen* adj9 shock*).tw,ot,kw. 18652
3 (circulator* adj3 shock*).tw,ot,kw. 1949
4 coron* shock*.tw,ot,kw. 32
5 acute circulatory fail*.tw,ot,kw. 465
6
*Shock/dt not (septic or sepsis or bacter*em* or infect* or endotoxin* or heat shock or HSP* or
anaphyl* or allergic or vasodilat* or osmotic or h?emorr* or bleeding or toxic or neurogen* or
burn* or shock-wave or shock-resistant or hypovolemic or electroconvuls* or distributive
shock*).ti.
1157
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7
((undifferent* or undiagnos* or different or various or variety or type or types or kind or kinds
or forms or states or etiologies) adj2 (shock* not heat shock*)).tw.
2735
8 or/1-7 [ I ] 32877
9
heart muscle ischemia/ or heart infarction/ or acute heart infarction/ or anterior myocardial
infarction/ or heart infarction size/ or exp heart ventricle infarction/ or non st segment elevation
myocardial infarction/ or posterior myocardial infarction/ or st segment elevation myocardial
infarction/ or exp percutaneous coronary intervention/ or percutaneous transluminal
angioplasty/ or coronary artery bypass graft/ or coronary artery bypass surgery/
547773
10
(((myocard* or heart or card* or ST) adj3 (infarct* or isch?em*)) or (coronary intervent* or STEMI
or PCI or angioplast* or post-isch* or postisch* or postinfarct* or post-infarct* or MI or AMI or
myocard* revasc* or coronary artery bypass* or CABG or aortocoronary bypass* or coronary
bypass*)).tw,ot,kw.
572593
11 9 or 10 [MI] 737611
12
(*shock/ or shock.ti.) not (exp heart stimulation/ or (septic or sepsis or bacter*em* or infect* or
endotoxin* or heat shock or HSP* or anaphyl* or allergic or vasodilat* or osmotic or h?emorr* or
bleeding or toxic or neurogen* or burn* or shock-wave or shock-resistant or hypovolemic or
electroconvuls* or distributive shock*).ti.) [shock general]
32315
13 forward heart failure/ 5518
14
((low* or diminish* or decreas* or declin* or reduc* or negligibl* or fall*) adj2 (card* or heart) adj
output*).tw,kw.
12569
15 ((low* or diminish* or decreas* or declin* or reduc* or negligibl*) adj output*).tw,kw. 2964
16 cardiac output low.tw,kw,ot. 105
17 (LCOS or COS or LCO).tw,ot,kw. 20242
18 ((instab* or unstab*) adj1 h?emodyn*).tw,kw. 12677
19 or/12-18 [shock, low CO] 81903
20 11 and 19 [ II = MI + CO ] 10001
21 8 or 20 [I II] 38501
22
(book or editorial).pt. or book/ or editorial/ or ((("review" or letter).pt. or "review"/ or letter/) not
(meta analysis/ or "systematic review"/ or clinical study/ or case control study/ or exp controlled
clinical trial/ or controlled study/ or intervention study/ or longitudinal study/ or major clinical
study/ or prospective study/ or retrospective study/ or cohort analysis/ or (systematic adj2
(literature or review)).tw,ot,kw.))
3896039
23
((animal/ or animal experiment/ or animal model/ or nonhuman/) not human/) or (porcine or
piglet or pig or pigs or rat or rats or dogs or dog or canine).ti. or ph?eochrom*.mp.
6420601
24 22 or 23 10059750
25 21 not 24 [I II - humans not editorials, reviews] 30861
26 *inotropic agent/ or inotropic agent/ae, ct, cb, cm, dt 6390
27 *cardiotonic agent/ or cardiotonic agent/ae, ct, cb, cm, dt 2726
28 catecholamine/ae, ct, cb, cm, dt 1671
29 (cardiotonic* or inopressor* or inodilator*).tw,ot,kw. 3739
30
(catecholamines or inotropes or vasopressors or ((catecholamine or inotrop* or vasopressor) adj3
(support or solution* or infusion* or dosing or dose* or dosage* or prescri* or "use" or therap* or
treat* or cotreat* or administ* or requir* or need* or superior or first-line or "add" or added or
addition or adding or receiv* or receipt or regimen* or alone or combin* or plus or compar* or
vs or versus or assigned or allocat* or randomi?ed or effectiveness or efficacy or drug* or agent*
or substance* or group))).tw,ot,kw.
74053
31 dopamine/ not (dopamine/ec not dopamine/ae, cb, cm, dt) 80557
32 (dopamin* or hydroxytyramin* or Intropin*).tw,ot,kw. 189228
33 dobutamine/ not (dobutamine/ec not dobutamine/ae, cb, cm, dt) 23435
34 dobutamin*.tw,ot,kw. 12411
35 noradrenalin/ not (noradrenalin/ec not noradrenalin/ae, cb, cm, dt) 114540
36 (norepinephrin* or noradrenalin*).tw,ot,kw. 120459
37 adrenalin/ not (adrenalin/ec not adrenalin/ae, cb, cm, dt) 111164
38 (epinephrin* or adrenalin*).tw,ot,kw. 83979
39 milrinone/ 7278
40 milrinon*.tw,ot,kw. 2706
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41 vasopressin/ not (vasopressin/ec not vasopressin/ad, cb, cm, dt) 29150
42 vasopressin*.tw,ot,kw. 41607
43 simendan/ 106
44 (simendan or levosimend*).tw,ot,kw. 2165
45 or/26-44 [drugs] 549646
46 25 and 45 [total] 5721
47 remove duplicates from 46 [total hits -deduplicated] 5640
48 (embase or elsevier or canadian).cr. 26116001
49 47 and 48 [ EMBASE records only] 5261
CENTRAL
ID Search Hits
#1 (cardiogen* near/9 shock*):ti,ab,kw 914
#2 (circulator* near/3 shock*):ti,ab,kw 36
#3 (coron* NEXT shock*):ti,ab,kw 0
#4 (acute NEXT circulatory NEXT fail*):ti,ab,kw 14
#5 ((undifferent* or undiagnos* or different or various or variety or type or types or kind or kinds
or forms or states or etiologies) near/2 shock*):ti,ab not (heat NEXT shock*):ti,ab
82
#6 #1 or #2 or #3 or #4 or #5 1036
#7 (((myocard* or heart or card* or ST) near/3 (infarct* or isch*em*)) or ((coronary NEXT
intervent*) or STEMI or PCI or angioplast* or (post NEXT isch*) or postisch* or postinfarct*
or (post NEXT infarct*) or MI or AMI or (myocard* NEXT revasc*) or (coronary NEXT artery
NEXT bypass*) or CABG or (aortocoronary NEXT bypass*) or (coronary NEXT bypass*)))
57969
#8 shock:ti,kw not (septic or sepsis or bacter*em* or infect* or endotoxin* or (heat NEXT shock) or
HSP* or anaphyl* or allergic or vasodilat* or osmotic or h*emorr* or bleeding or toxic or
neurogen* or burn* or (shock NEXT wave) or (shock NEXT resistant) or hypovolemic or (hypo
NEXT volemic) or electroconvuls* or (distributive NEXT shock*)):ti
2559
#9 ((low* or diminish* or decreas* or declin* or reduc* or negligibl* or fall*) near/2 ((card* NEXT
output) OR (heart NEXT output))):ti,ab,kw
1094
#10 ((low* or diminish* or decreas* or declin* or reduc* or negligibl*) next output*):ti,ab,kw 138
#11 (LCOS or COS or LCO):ti,ab,kw 312
#12 ((instab* or unstab*) near/1 h*emodyn*):ti,ab,kw 633
#13 #8 or #9 or #10 #11 or #12 4238
#14 #7 and #13 1078
#15 #6 or #14 1595
#16 (cardiotonic* or inopressor* or inodilator* or dopamin* or hydroxytyramin* or Intropin* or
dobutamin* or norepinephrin* or noradrenalin* or epinephrin* or adrenalin* or milrinon* or
vasopressin* or simendan or levosimend*):ti,ab,kw
22220
#17 (catecholamines or inotropes or vasopressors or ((catecholamine or inotrop* or vasopressor)
near/3 (support or solution* or infusion* or dosing or dose* or dosage* or prescri* or "use" or
therap* or treat* or cotreat* or administ* or requir* or need* or superior or (first NEXT line) or
"add" or added or addition or adding or receiv* or receipt or regimen* or alone or combin* or
plus or compar* or vs or versus or assigned or allocat* or randomi*ed or effectiveness or efficacy
or drug* or agent* or substance* or group))):ti,ab,kw
4646
#18 #16 or #17 24628
#19 #15 and #18 277
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